RxDoctor Payments Data

Glenda Gonzalez Couvertier, MD

Internal Medicine · Lake Mary, FLNPI 1508859299

Payments from drug & device makers

$2,967in general payments, 2019–2025

Across 166 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$469
  • AstraZeneca$393
  • AbbVie$349
  • Lilly USA, LLC$328
  • Novo Nordisk$272
  • Amarin Pharma, Inc.$223
  • plus $932 from 13 others

What the payments were for

  • Food & beverage$2,93799%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,967 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$2,970
Medicare patients
12
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$23,594
JardianceEmpagliflozin18$20,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,964
JanuviaSitagliptin Phosphate19$18,514
EliquisApixaban17$16,594
Janumet XrSitagliptin Phos/Metformin Hcl16$10,642
LantusInsulin Glargine,hum.Rec.Anlog11$2,667
Rosuvastatin Calcium127$2,302
Albuterol Sulfate HfaAlbuterol Sulfate63$1,883
SynthroidLevothyroxine Sodium14$1,735
Atorvastatin Calcium122$1,154
Losartan Potassium125$1,121
Gabapentin80$1,083
Lidocaine13$937
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide19$919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$111$29,15635 claims
Novo NordiskOzempic$272$23,59423 claims
Boehringer IngelheimJardiance$106$20,16218 claims
GSKTrelegy Ellipta$469$19,96428 claims
PfizerEliquis$175$16,59417 claims
AbbVieSynthroid$349$1,73514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →